We would love to hear your thoughts about our site and services, please take our survey here.
China have so far mostly got the handle of this virus but I dont think they're out of the woods yet.
There are still local transmissions there and throw in a more infectious variant, as they say what goes around comes around.
Maybe the uk could sell them back their crappy innova tests before sending plane loads of Avacta lfts over.. £500 in China lol
AJ in the video description it says;
He also mentioned there was a major announcement this week which you can find out more about here
https://lnkd.in/e7-N4QQ
The big announcement in the vid was as we all know about the Bruker financing partnership.
https://www.businesswire.com/news/home/20210106005853/en/Adeptrix-Closes-Series-A-Financing-to-Commercialize-BAMS%E2%84%A2-Bioanalytical-Reagents-for-Life-Science-Research
Since Adeptrix are presumably happy with the performance of the covid affimers, I wonder will they look to using other affimers when expanding the affi-bams assays?
Dr. Rohan A. Thakur, EVP of Life Sciences Mass Spectrometry at Bruker Daltonics, commented: “Our partnership with Adeptrix is important as it enables wider access to critical BAMS assay technology for translational research using MALDI-TOF mass spectrometry, which is capable of analyzing thousands of samples per day. Our partnership is expected to accelerate collaborations with developers of antibodies and other affinity reagents to expand the range of available protein biomarker Affi-BAMS assays for liquid biopsies, cell and tissue-based applications.”
Great thread by all cheers.
Sorry I actually missed a part of the financial considerations out.
Financial considerations
AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments: $350m is due upon completion, with $325m after 12 months and $325m after 24 months from the effective date of the agreement.
AstraZeneca will pay additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones.
Apologies if already posted/
The Uk is co.cking up again, crazy.
https://www.nytimes.com/2021/01/01/health/coronavirus-vaccines-britain.html
ES this is not a buyout but dont forget this deal from July 2020.
AstraZeneca and Daiichi Sankyo enter collaboration to
develop and commercialise new antibody drug conjugate
Financial considerations
AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments: $350m is due upon completion, with $325m after 12 months and $325m after 24 months from the effective date of the agreement.
Potential new medicine DS-1062 could redefine treatment
standards in lung, breast and multiple other cancers
AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types.
DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. Among them, TROP2 is overexpressed in the majority of non-small cell lung cancers1 and breast cancers,2,3 tumour types that have long been a strategic focus for AstraZeneca. This collaboration reflects AstraZeneca's strategy to invest in antibody drug conjugates as a class, the innovative nature of the technology and the successful existing collaboration with Daiichi Sankyo.
Pascal Soriot, Chief Executive Officer, said: " We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2. We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of Enhertu to further expand our pipeline and leadership in Oncology. We now have six potential blockbusters in Oncology with more to come in our early and late pipelines."
Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo, said: "DS-1062, one of our lead DXd ADCs that will form a pillar of our next mid-term business plan, has the potential to become a best-in-class TROP2 ADC in multiple tumours, including lung and breast cancers. This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible. As we have done with Enhertu, we will jointly design and implement strategies to maximise the value of DS-1062."
Using Daiichi Sankyo's proprietary DXd ADC technology, DS-1062 is designed to deliver chemotherapy selectively to cancer cells and to reduce systemic exposure. A comprehensive development programme with DS-1062 is planned globally.
Thanks for thst info kford.
I dont read these boards often so never noticed thst.
Ive a reasonable investment here, kinda dont feel the need to constantly check developments as I feel its fairly safe medium/long term investment.
Gl with the morons ..too many on these boards for sure.
Hes a complete moron, cant say for sure but could be someone from the AVCT bb, reason being there was a handfull of moron ODX posters over there verbally attacking that board. Please dont take this as a que to land over on the AVCT bb though.
Seriously fecking morons the lot of them.
These boards would be a lot better all round if each avatar was identity checked.
One person one account, peoples behaviour would be a lot different i suspect.
Gla
Good pipeline ADCT have.
Worth noting their MCAP is over $2.5 billion with revenue of £2.3 million.
AVCT has a great pipeline, when Precision and TMAC are in clinical trials what could the MCAP be?
I had researched this a bit during Attis days a few months back and had went off the radar.
Just seen the helium1 ipo a few days ago and have now bought a modest holding here, it has huge potential upside.
If assets are proven and helium starts production, a while away i know, then its multiples of mcap from here.
I have a figure in mind but dont want to be too rampy :)
Long term hold for this.
Tbh hope this drops a bit and I will build a larger position.
Gla.